Medication info

Lostel Tablets 80/20 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets ((10 tablets/Alu-Alu)x3)
Approval status
Expired

MFDS item code 201506822 · Approved 2015.09.25

This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after initiation of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who require the combined administration of telmisartan and rosuvastatin. Telmisartan is primarily used to treat essential hypertension and reduce the risk of cardiovascular disease, particularly in high-risk patients aged 55 and older, reducing the risk of myocardial infarction, stroke, and cardiovascular death. Rosuvastatin is used as an adjunct to diet for treating hypercholesterolemia and hyperlipidemia, delaying atherosclerosis and reducing the risk of cardiovascular disease and stroke in high-risk groups. Thus, these two medications help improve cardiovascular health by managing blood pressure and blood lipids simultaneously.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after initiation of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This drug can cause serious harm or death to the fetus and newborn, especially during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any of the components of this drug, pregnant or breastfeeding women, patients with severe liver dysfunction, severe kidney dysfunction, muscle diseases, and certain genetic disorders should not take this medication. Elderly patients or those with hyperkalemia, weakened liver function, cardiovascular diseases, gastrointestinal diseases, and renal artery hypertension should take this medication with caution. If symptoms such as myalgia, muscle weakness, or muscle cramps appear, consult a doctor immediately, and in severe cases, discontinue use of the drug. Side effects such as liver dysfunction, hypotension, headache, dizziness, dyspepsia, and myalgia may occur, so if symptoms are severe or persist, consult a healthcare professional. There may be interactions with other medications, so it’s essential to inform your doctor or pharmacist of any other medications being taken. Women who are pregnant or planning to become pregnant should consult healthcare professionals before taking this medication and should use adequate contraceptive methods. The safety of this drug in children has not been established; hence its use is not recommended. In cases of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, necessitating immediate medical attention. Caution should be exercised as drowsiness or dizziness may occur while driving or operating machinery. Medications should be stored out of the reach of children and should not be transferred to other containers.

Side effects

Headache, orthostatic dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disorders, benign gastrointestinal neoplasms, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, increased urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, indigestion, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver dysfunction, liver impairment, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, angioedema, hypersensitivity reactions, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, facial twitching, sensation abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, ear noise, petechiae, palpitations, fatigue, nausea, inadequate effect, headache, dizziness, cough, indigestion, palpitations, joint pain, fatigue, numbness, sensation abnormalities, chest discomfort, loss of appetite, abdominal bloating, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container as it may be sensitive to air or moisture. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. Proper storage will help preserve the efficacy of the medication.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets ((10 tablets/Alu-Alu)x3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.